Alteogen
About Alteogen
Categories
-
KR -
2023On CPHI since
Products from Alteogen (3)
-
Product Eylea® Aflibercept Biosimilar ALT-L9
Indications: Wet Age-related Macular Degeneration (wAMD). Currently in global phase III and to be launched by 2025. Same cell line used by originator and has a high level of similarity in PK profile in human studies. ALT-L9 has a unique formulation with improved thermal stability with process patents regis... -
Product Novel Hyaluronidase (ALT-B4) Hybrozyme™
A novel and proprietary hyaluronidase to enable subcutaneous administration of IV biologics. Currently partnered with 4 global pharmaceutical companies including two Top 10 global pharmaceutical companies. ALT-B4 has enhanced thermal stability and protein stability leading to longer shelf-life, has higher ... -
Product Novel Hyaluronidase Human Injection Tergase®
Novel hyaluronidase exhibiting enhanced properties - higher tolerance to thermal stress, specific activity and productivity and lower immunogenicity. Indications in dermatology, ophthalmology, pain management and plastic surgery. Tergase® is a substantially better alternative to animal-derived hyaluronidas...
Alteogen Resources (1)
-
Brochure Alteogen signs global licence deal with Sandoz
Sandoz will have global rights to use Alteogen’s ALT-B4 to develop and commercialise a subcutaneous version of a biosimilar product.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance